The drug blocking the inhibition of CD39 activity can not only block the mitochondrial metabolic reprogramming related to AraC resistance but also significantly enhance its cytotoxicity and sensitivity to AML cells in vivo and in vitro (64, 65). The gene discussed is ENTPD1; the disease is acute myeloid leukemia.